University of Miami's 2nd Biennial Miami Leukemia Symposium

 

University of Miami's 2nd Biennial Miami Leukemia Symposium
D

Discussion on the Data of Frontline Combination Therapy with APR-246 + Azacitidine in TP53 MT HMA-naive MDS and Oligoblastic AML

By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING David Sallman
By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING David Sallman
11 views
May 14, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
MDS Biology and Treatment
25:42
University of Miami's 2nd Biennial Miami Leukemia Symposium

2020 Update on MDS Mutational Landscape: What Are the Most Common MD…

Feat. R. Bejar
20:06
University of Miami's 2nd Biennial Miami Leukemia Symposium

2020 Update on Splicing in MDS: How Can We Target Spliceosome-Mutant…

Feat. T. Graubert
22:02
University of Miami's 2nd Biennial Miami Leukemia Symposium

TGF Beta Pathway Inhibition in MDS: Luspatercept Significantly Decre…

Feat. A. Verma
12:19
University of Miami's 2nd Biennial Miami Leukemia Symposium

How to Calculate Risk in MDS Patients?

Feat. M. Sekeres
14:36
University of Miami's 2nd Biennial Miami Leukemia Symposium

Frontline Therapies in MDS: Leveling Lower-risk MDS

Feat. M. Sekeres
05:28
University of Miami's 2nd Biennial Miami Leukemia Symposium

Frontline Therapies in MDS: Hampering Higher-risk MDS

Feat. M. Sekeres
10:48
University of Miami's 2nd Biennial Miami Leukemia Symposium

Hypomethylating Agents as SoC in MDS/AML: Clearance of TP53 Mutation…

Feat. D. Sallman
08:13
University of Miami's 2nd Biennial Miami Leukemia Symposium

Discussion on the Data of Frontline Combination Therapy with APR-246…

Feat. D. Sallman
05:21
University of Miami's 2nd Biennial Miami Leukemia Symposium

Magrolimab (Formerly 5F9) is a First-in-class Macrophage Immune Chec…

Feat. D. Sallman
27:33
University of Miami's 2nd Biennial Miami Leukemia Symposium

Overcoming Adaptive Therapy Resistance in AML: IRAK Signalling (via …

Feat. D. Starczynowski